Here is today's release for those interested:
November 19, 1997
NORTRAN PHARMACEUTICALS INC ("NRT-V;NTRDF-L")
- Collaborates With Bridge Pharma To Develop Dermal Anesthetics
Michael J. A. Walker, Ph.D., Chairman of Nortran Pharmaceuticals Inc. is pleased to announce that it has signed an agreement with Bridge Pharma Inc., a private pharmaceutical research and development company based in Sarasota Florida, to collaborate on the research and development of a series of novel dermal anesthetic
compounds.
Under the terms of this agreement, Bridge Pharma will manage and conduct studies aimed at selecting a compound for testing in human clinical trials. Nortran will fund these studies and in return Nortran will receive rights to the dermal uses of these compounds and will pay Bridge a 25 percent royalty on Nortran's revenues from this project.
"We are pleased to begin this collaboration which is strategically aligned with our technology focus in ion channel pharmacology and our disease focus in pain management," stated Dr. Allen Bain, President of Nortran. "Bridge's knowledge and experience in drug discovery and development will complement Nortran's own such capabilities."
Nortran's mission is to capture creativity to discover important new drugs. Nortran has developed a unique system of identifying and nurturing scientific creativity. This system is specifically designed to develop novel approaches to treating diseases where there exists an obvious unmet need. Each project is championed by a world expert.
Dr. Aberg, President of Bridge Pharma, Inc., stated "We look forward to working with Nortran in the area of dermal anesthesia, where there is a very obvious need for improved therapy." Prior to founding Bridge Pharma, Dr. Aberg held several senior research and development positions with major pharmaceutical companies including Sepracor Inc., Bristol-Myers Squibb, Ciba-Geigy, and Astra. Dr. Aberg has been involved in successful research and product development resulting in
antihistamines, antihypertensives, antiarrhythmics and local anesthetics that are now on the market.
Nortran Pharmaceuticals Inc. is a drug discovery company whose focus is pathology targeted small molecules. Nortran's current drugs in development target the ion channels responsible for life-threatening arrhythmias of the heart and for intractable pain.
TEL: (604) 822-2278 Sue Milne, Investor Relations TEL: 1-800-330-9928 Nortran Pharmaceuticals Inc. FAX: (604) 822-9578
Internet: nortran.com
______________________________
(c) Corporate Dissemination Services Inc. All rights reserved. |
